| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Chinook Therapeutics Inc (NASDAQ: KDNY)
KDNY Technical Analysis
5
| As on 9th Jun 2023 KDNY STOCK Price closed @ 23.99 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 17.18 & Strong Buy for SHORT-TERM with Stoploss of 13.83 we also expect STOCK to react on Following IMPORTANT LEVELS. |
KDNYSTOCK Price
| Open | 24.01 | Change | Price | % |
| High | 24.23 | 1 Day | 0.04 | 0.17 |
| Low | 23.75 | 1 Week | 0.68 | 2.92 |
| Close | 23.99 | 1 Month | 1.99 | 9.05 |
| Volume | 419633 | 1 Year | 8.29 | 52.80 |
| 52 Week High 27.35 | 52 Week Low 12.02 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| KDNY Daily Charts |
KDNY Intraday Charts |
Whats New @ Bazaartrend |
KDNY Free Analysis |
|
|
KDNY Important Levels Intraday
| RESISTANCE | 24.91 |
| RESISTANCE | 24.62 |
| RESISTANCE | 24.43 |
| RESISTANCE | 24.25 |
| SUPPORT | 23.73 |
| SUPPORT | 23.55 |
| SUPPORT | 23.36 |
| SUPPORT | 23.07 |
KDNY Forecast May 2024
| 4th UP Forecast | 34.28 |
| 3rd UP Forecast | 30.98 |
| 2nd UP Forecast | 28.94 |
| 1st UP Forecast | 26.9 |
| 1st DOWN Forecast | 21.08 |
| 2nd DOWN Forecast | 19.04 |
| 3rd DOWN Forecast | 17 |
| 4th DOWN Forecast | 13.7 |
KDNY Weekly Forecast
| 4th UP Forecast | 26.96 |
| 3rd UP Forecast | 26.01 |
| 2nd UP Forecast | 25.42 |
| 1st UP Forecast | 24.83 |
| 1st DOWN Forecast | 23.15 |
| 2nd DOWN Forecast | 22.56 |
| 3rd DOWN Forecast | 21.97 |
| 4th DOWN Forecast | 21.02 |
KDNY Forecast2024
| 4th UP Forecast | 55.36 |
| 3rd UP Forecast | 45.3 |
| 2nd UP Forecast | 39.08 |
| 1st UP Forecast | 32.86 |
| 1st DOWN Forecast | 15.12 |
| 2nd DOWN Forecast | 8.9 |
| 3rd DOWN Forecast | 2.68 |
| 4th DOWN Forecast | -7.38 |
Chinook Therapeutics Inc ( NASDAQ USA Symbol : KDNY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
KDNY Business Profile
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington. Address: 1600 Fairview Avenue East, Seattle, WA, United States, 98102
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service